3
Clinical Trials associated with Torsemide/SpironolactoneSarfez Pharmaceuticals Inc. - A Randomized, Parallel, TwoArm Study Comparing the Net Clinical Benefit of Finerenone Versus a FixedDose Combination of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and PRoteinuric ChrOnic KidNey Disease
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.
An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
100 Clinical Results associated with Torsemide/Spironolactone
100 Translational Medicine associated with Torsemide/Spironolactone
100 Patents (Medical) associated with Torsemide/Spironolactone
100 Deals associated with Torsemide/Spironolactone